The first precision therapy for children with achondroplasia, vosoritide, is now approved in many regions, including Australia, the USA, the European Union and Japan. This article discusses the recent trial results for this therapy regarding growth and the co-morbidities associated with achondroplasia and considers the rationale for its clinical use.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hoover-Fong, J. et al. Lifetime impact of achondroplasia: Current evidence and perspectives on the natural history. Bone 146, 115872 (2021).
Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335–342 (1994).
Savarirayan, R. et al. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat. Rev. Endocrinol. 18, 173–189 (2022).
Savarirayan, R. et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N. Engl. J. Med. 381, 25–35 (2019).
Savarirayan, R. et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet 396, 684–692 (2020).
Savarirayan, R. et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child Adolesc. Health 8, 40–50 (2024).
Savarirayan, R. et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet. Med. 23, 2443–2447 (2021).
Savarirayan, R. et al. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery. Sci. Prog. 104, 368504211003782 (2021).
Savarirayan, R., Hoover-Fong, J., Yap, P. & Fredwall, S. O. New treatments for children with achondroplasia. Lancet Child Adolesc. Health 8, 301–310 (2024).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.S. has received honoraria from BioMarin, QED pharma, Ascendis and Sanofi.
Rights and permissions
About this article
Cite this article
Savarirayan, R. Advances in the management of achondroplasia. Nat Rev Endocrinol (2024). https://doi.org/10.1038/s41574-024-00994-w
Published:
DOI: https://doi.org/10.1038/s41574-024-00994-w